Underutilization of medications to treat opioid use disorder: What role does stigma play?

References

• Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths – United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–1382.
   PubMed Web of Science ®Google Scholar
• Mack KA, Jones CM, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas – United States. MMWR Morb Mortal Wkly Rep. 2017;66(19):1–12.
   PubMedGoogle Scholar
• Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2005–2015. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-91, HHS Publication No. (SMA) 17-5037. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.
   Google Scholar
• American Society of Addiction Medicine. National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Chevy Chase, MD: ASAM; 2015.
   Google Scholar
• National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936–1943.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018;169(3):137–145.
   PubMed Web of Science ®Google Scholar
• Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–225.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu L. National trends and characteristics of inpatient detoxification for drug use disorders in the United States. BMC Pub Health. 2018;18:1073.
   PubMed Web of Science ®Google Scholar
• Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up study. BMJ. 2003;326(7396):959–960.
   PubMed Web of Science ®Google Scholar
• Bruneau J, Ahamad K, Goyer MÈ, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247–E257.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;(2):CD002209.
   Google Scholar
• Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–318.
   PubMed Web of Science ®Google Scholar
• Krawczyk N, Picher CE, Feder KA, Saloner B. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff. 2017;36(12):2046–2053.
   PubMed Web of Science ®Google Scholar
• New York City Department of Health and Mental Hygiene. Unpublished data, New York, NY; 2018.
   Google Scholar
• Sheehan L, Nieweglowski K, Corrigan PW. Structures and types of stigma. In: Gaebel W, Rossler W, Sartorius N, eds. The Stigma of Mental Illness – the End of the Story? New York, NY: Springer; 2017:67–82.
   Google Scholar
• Link BG, Phelan J. Social conditions as fundamental causes of disease. J Health Soc Behav. 1995;35:80–94.
   Web of Science ®Google Scholar
• Kelly JF, Wakeman SE, Saitz R. Stop talking ‘dirty’: clinicians, language, and quality of care for the leading cause of preventable death in the United States. Am J Med. 2015;128(1):8–9.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Pham-Kanter G, Donelan K. Attitudes, practices, and preparedness to care for patients with substance use disorder: results from a survey of general internists. Subst Abus. 2016;37(4):635–641.
   PubMed Web of Science ®Google Scholar
• Saloner B, Stoller KB, Alexander GC. Moving addiction care to the mainstream: improving the quality of buprenorphine treatment. N Engl J Med. 2018;379(1):4–6.
   PubMed Web of Science ®Google Scholar
• Stone J, Fraser H, Lim AG, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Inf Dis. 2018;18(12):1397–1409.
   PubMed Web of Science ®Google Scholar
• Forrest AR. Ethical aspects of workplace urine screening for drug abuse. J Med Ethics. 1997;23(1):12–17.
   PubMed Web of Science ®Google Scholar
• Link BG, Phelan J. Conceptualizing stigma. Ann Rev Sociol. 2001;27:363–385.
   Web of Science ®Google Scholar
• Brown SA. Standardized measures for substance use stigma. Drug Alcohol Depend. 2011;116(1–3):137–141.
   PubMed Web of Science ®Google Scholar
• Smith LR, Earnshaw VA, Copenhaver MM, Cunningham CO. Substance use stigma: Reliability and validity of a theory-based scale for substance-using populations. Drug Alcohol Depend. 2016;162:34–43.
   PubMed Web of Science ®Google Scholar
• Kennedy-Hendricks A, Busch SH, McGinty EE, et al. Primary care physicians’ perspectives on the prescription opioid epidemic. Drug Alcohol Depend. 2016;165:61–70.
   PubMed Web of Science ®Google Scholar
• Woo J, Bhalerao A, Bawor M, et al. “Don’t judge a book by its cover”: a qualitative study of methadone patients’ experiences of stigma. Subst Abuse. 2017;11:1–12.
   Google Scholar
• Hatcher AE, Mendoza S, Hansen H. At the expense of a life: race, class, and the meaning of buprenorphine in pharmaceuticalized “care.” Subst Use Misuse. 2018;53(2):301–310.
   PubMed Web of Science ®Google Scholar
• Knight KR. Addicted.Pregnant.Poor. Durham, NC: Duke Univ. Press; 2015.
   Google Scholar
• Kennedy-Hendricks A, Busch SH, McGinty EE, et al. Primary care physicians’ perspectives on the prescription opioid epidemic. Drug Alcohol Depend. 2016;165:61–70.
   PubMed Web of Science ®Google Scholar
• Tiger R. Judging addicts: drug courts and coercion in the justice system. New York, NY: New York Univ. Press; 2012.
   Google Scholar
• Avery J, Dixon L, Adler D, et al. Psychiatrists’ attitudes toward individuals with substance use disorders and serious mental illness. J Dual Diag. 2013;9(4):322–326.
   Web of Science ®Google Scholar
• Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104–110.
   PubMed Web of Science ®Google Scholar
• Kelly JF, Wakeman SE, Saitz R. Stop talking ‘dirty’: clinicians, language, and quality of care for the leading cause of preventable death in the United States. Am J Med. 2015;128(1):8–9.
   PubMed Web of Science ®Google Scholar
• Baker KM. “I’m going to shut down all of your tricks”: depictions of treatment professionals in addiction entertainment. Subst Use Misuse. 2016;51(4):489–497.
   PubMed Web of Science ®Google Scholar
• Netherland J, Hansen HB. The war on drugs that wasn’t: wasted whiteness, “dirty doctors,” and race in media coverage of prescription opioid misuse. Cult Med Psychiatry. 2016;40(4):664–686.
   PubMed Web of Science ®Google Scholar
• Wakeman SE. Language and addiction: choosing words wisely. Am J Public Health. 2013;103(4):e1–e2.
   PubMed Web of Science ®Google Scholar
• Kulesza M, Larimer ME, Rao D. Substance use related stigma: what we know and the way forward. J Addict Behav Ther Rehabil. 2013;2(2):pii: 782.
   PubMedGoogle Scholar
• Wakeman SE, Pham-kanter G, Donelan K. Attitudes, practices, and preparedness to care for patients with substance use disorder: results from a survey of general internists. Subst Abus. 2016;37(4):635–641.
   PubMed Web of Science ®Google Scholar
• P Goddu A, O’Conor KJ, Lanzkron S, et al. Do words matter? Stigmatizing language and the transmission of bias in the medical record. J Gen Intern Med. 2018;33(5):685–691.
   PubMed Web of Science ®Google Scholar
• Gryczynski J, Jaffe JH, Schwartz RP, et al. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013;22(3):285–291.
   PubMed Web of Science ®Google Scholar
• Stancliff S, Myers JE, Steiner S, Drucker E. Beliefs about methadone in an inner-city methadone clinic. J Urban Health. 2002;79(4):571–578.
   PubMed Web of Science ®Google Scholar
• Matthews S, Dwyer R, Snoek A. Stigma and self-stigma in addiction. J Bioeth Inq. 2017;14(2):275–286.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330–333.
   PubMed Web of Science ®Google Scholar
• Allen B, Harocopos A. Non-prescribed buprenorphine in New York City: motivations for use, practices of diversion, and experiences of stigma. J Subst Abuse Treat. 2016;70:81–86.
   PubMed Web of Science ®Google Scholar
• Woods JS, Joseph H. Stigma from the viewpoint of the patient. J Addict Dis. 2015;34(2–3):238–247.
   PubMed Web of Science ®Google Scholar
• Hiltunen AJ, Eklund C. Withdrawal from methadone maintenance treatment. Reasons for not trying to quit methadone. Eur Addict Res. 2002;8(1):38–44.
   PubMed Web of Science ®Google Scholar
• Buchman D, Reiner PB. Stigma and addiction: being and becoming. Am J Bioeth. 2009;9(9):18–19.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, O’Grady KE, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008;17:396–401.
   PubMed Web of Science ®Google Scholar
• Shah PA, Sohler NL, López C, Fox AD, Cunningham CO. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program. J Opioid Manag. 2013;9:407–413.
   PubMedGoogle Scholar
• Krawczyk N, Feder KA, Fingerhood MI, Saloner B. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. Drug Alcohol Depend. 2017;178:512–518.
   PubMed Web of Science ®Google Scholar
• Feagin J, Bennefield Z. Systemic racism and U.S. health care. Soc Sci Med. 2014;103:7–14.
   PubMed Web of Science ®Google Scholar
• Windsor LC, Negi N. Substance abuse and dependence among low income African Americans: using data from the national survey on drug use & health to demystify assumptions. J Addict Dis. 2009;28(3):258–268.
   PubMed Web of Science ®Google Scholar
• Bourgois P. Disciplining addictions: the bio-politics of methadone and heroin in the United States. Cult Med Psychiatry. 2000;24(2):165–195.
   PubMed Web of Science ®Google Scholar
• Mendoza S, Rivera-cabrero AS, Hansen H. Shifting blame: buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America. Transcult Psychiatry. 2016;53(4):465–487.
   PubMed Web of Science ®Google Scholar
• Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14–21.
   PubMed Web of Science ®Google Scholar
• Tuazon E, Kunins H, Paone D. Buprenorphine and methadone dispensing in New York City. New York, NY: New York City Department of Health and Mental Hygiene: Epi Data Brief (96); November 2017.
   Google Scholar
• Came H, Griffith D. Tackling racism as a “wicked” public health problem: enabling allies in anti-racism praxis. Soc Sci Med. 2018;199:181–188.
   PubMed Web of Science ®Google Scholar
• Maina IW, Belton TD, Ginzberg S, Singh A, Johnson TJ. A decade of studying implicit racial/ethnic bias in healthcare providers using the implicit association test. Soc Sci Med. 2018;199:219–229.
   PubMed Web of Science ®Google Scholar
• Doernberg M, Krawczyk N, Agus D, Fingerhood M. Demystifying buprenorphine misuse: has fear of diversion gotten in the way of addressing the opioid crisis? Subst Abus. 2019;1–6.
   Web of Science ®Google Scholar
• Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463.
   PubMed Web of Science ®Google Scholar
• Jee-Lyn García J, Sharif MZ. Black lives matter: a commentary on racism and public health. Am J Public Health. 2015;105(8):e27–e30.
   PubMed Web of Science ®Google Scholar
• Kelly JF, Saitz R, Wakeman S. Language, substance use disorders, and policy: the need to reach consensus on an “addiction-ary.” Alc Treat Quar. 2016;34(1):116–123.
   Web of Science ®Google Scholar
• Wakeman SE. Medications for addiction treatment: changing language to improve care. J Addict Med. 2017;11(1):1–2.
   PubMed Web of Science ®Google Scholar
• Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O’Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103(3):462–468.
   PubMed Web of Science ®Google Scholar
• Dick AW, Pacula RL, Gordon AJ, et al. Increasing potential access to opioid agonist treatment in US treatment shortage areas. Health Aff. 2015;34(6):1028–1034.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
   PubMed Web of Science ®Google Scholar
• New York City Department of Health and Mental Hygiene. “Living Proof”. https://www1.nyc.gov/assets/doh/downloads/pdf/basas/opioid-living-proof-campaign.pdf. Accessed September 13, 2018.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.
   Google Scholar
• Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after federal oversight. Can J Psychiatry. 2017;62(7):444–450.
   PubMed Web of Science ®Google Scholar
• Poloméni P, Schwan R. Management of opioid addiction with buprenorphine: French history and current management. Int J Gen Med. 2014;7:143–148.
   PubMedGoogle Scholar
• Green TC, Case P, Fiske H, et al. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. J Am Pharm Assoc. 2017;57(2S):S19–S27.e4.
   Google Scholar
• Werb D, Kamarulzaman A, Meacham MC, et al. The effectiveness of compulsory drug treatment: a systematic review. Int J Drug Policy. 2016;28:1–9.
   PubMed Web of Science ®Google Scholar
• Ard KL, Edelstein ZR, Bolduc P, et al. Public health detailing for HIV pre-exposure prophylaxis. Clin Infect Dis. 2019;68(5):860–864.
   PubMed Web of Science ®Google Scholar
• Safi AG, Perin J, Mantsios A, Schumacher C, Chaulk CP, Jennings JM. Public health detailing to increase routine HIV screening in Baltimore, Maryland: Satisfaction, feasibility, and effectiveness. Public Health Rep. 2017;132(6):609–616.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, Switzerland: World Health Organization; 2009.
   Google Scholar
• Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the “narc” cabinet. J Gen Intern Med. 2002;17(5):327–333.
   PubMed Web of Science ®Google Scholar
• Neufeld KJ, Alvanzo A, King VL, et al. A collaborative approach to teaching medical students how to screen, intervene, and treat substance use disorders. Subst Abus. 2012;33(3):286–291.
   PubMed Web of Science ®Google Scholar
• Jaworsky D, Gardner S, Thorne JG, et al. The role of people living with HIV as patient instructors – reducing stigma and improving interest around HIV care among medical students. AIDS Care. 2017;29(4):524–531.
   PubMed Web of Science ®Google Scholar
• Silins E, Conigrave KM, Rakvin C, Dobbins T, Curry K. The influence of structured education and clinical experience on the attitudes of medical students towards substance misusers. Drug Alcohol Rev. 2007;26(2):191–200.
   PubMed Web of Science ®Google Scholar